報價延遲最少15分鐘:2025/02/22 17:54 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
29.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.34/7.24
|
|
企業價值
1.45B
|
| 資產負債 |
|
每股賬面淨值
7.26
|
| 現金流量 |
|
現金流量率
0.14
|
| 損益表 |
|
收益
566.77M
|
|
每股收益
16.95
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/22 17:54 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |